![Marc Voigt](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Marc Voigt
Chief Executive Officer at
IMMUTEP LIMITED
Net worth: 351 850 $ as of 2026-09-29
Profile
Mr. Marc Voigt is a Chairman-Supervisory Board & President at Immutep SAS, a Chief Executive Officer & Executive Director at Immutep Ltd., a Co-Managing Director at Immutep GmbH and a Member at Pharma-Lizenz-Club Deutschland.
He is on the Board of Directors at Immutep Ltd. Mr. Voigt was previously employed as a Vice Chairman-Supervisory Board by Elanix Biotechnologies AG, a MD, Chief Operating & Financial Officer by caprotec bioanalytics GmbH, a Chief Financial Officer by Revotar Biopharmaceuticals AG, a Director-Executive Board by Allianz SE, a Principal by Allianz Versicherungs AG, a Director-Finance, Legal & Business Development by Medical Enzymes AG, and a General Manager-European Operations by Immutep GmbH.
He received his MBA from Freie Universität Berlin.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IMMUTEP LTD 1.01% | 2026-03-17 | 14,877,395 ( 1.01% ) | 351 850 $ | 2026-09-29 |
Marc Voigt active positions
| Companies | Position | Start |
|---|---|---|
| IMMUTEP LIMITED | Chief Executive Officer | 2014-07-08 |
Pharma-Lizenz-Club Deutschland | Corporate Officer/Principal | - |
Immutep SAS
 Immutep SAS Pharmaceuticals: MajorHealth Technology Develops T-cell response-based immuno therapeutics for the treatment of cancer and infectious diseases | Chairman | 2015-11-17 |
Immutep GmbH
 Immutep GmbH BiotechnologyHealth Technology Develops novel immunotherapy treatments for cancer and autoimmune disease | Chief Executive Officer | - |
Former positions of Marc Voigt
| Companies | Position | End |
|---|---|---|
Medical Enzymes AG
 Medical Enzymes AG Medical/Nursing ServicesHealth Services Develops product family based on amino acid depleting enzymes | Director of Finance/CFO | 2006-01-01 |
Revotar Biopharmaceuticals AG
 Revotar Biopharmaceuticals AG Pharmaceuticals: MajorHealth Technology Develops anti-inflammatory drugs | Director of Finance/CFO | 2006-01-01 |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Develops novel immunotherapy treatments for cancer and autoimmune disease | Corporate Officer/Principal | - |
| ELANIX BIOTECHNOLOGIES AG | Director/Board Member | - |
caprotec bioanalytics GmbH
 caprotec bioanalytics GmbH BiotechnologyHealth Technology Commercializes Capture Compound Mass Spectrometry technology | Director of Finance/CFO | - |
Education of Marc Voigt
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
41
1st degree connections
11
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 11 |
|---|---|
Allianz SE
 Allianz SE Multi-Line InsuranceFinance Provides property, casualty, life and health insurance & asset management services | Finance |
Immutep Ltd.
 Immutep Ltd. BiotechnologyHealth Technology Engages in the development of anti-cancer therapeutics | Health Technology |
Elanix Biotechnologies AG
 Elanix Biotechnologies AG BiotechnologyHealth Technology Develops and commercializes products for acute wound care, dermatological, and gynecological applications | Health Technology |
Revotar Biopharmaceuticals AG
Revotar Biopharmaceuticals AG Pharmaceuticals: MajorHealth Technology Develops anti-inflammatory drugs | Health Technology |
Allianz Versicherungs AG
 Allianz Versicherungs AG Multi-Line InsuranceFinance Provides motor, property, liability and accident insurance services | Finance |
Freie Universität Berlin
 Freie Universität Berlin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
caprotec bioanalytics GmbH
caprotec bioanalytics GmbH BiotechnologyHealth Technology Commercializes Capture Compound Mass Spectrometry technology | Health Technology |
Medical Enzymes AG
Medical Enzymes AG Medical/Nursing ServicesHealth Services Develops product family based on amino acid depleting enzymes | Health Services |
Immutep SAS
Immutep SAS Pharmaceuticals: MajorHealth Technology Develops T-cell response-based immuno therapeutics for the treatment of cancer and infectious diseases | Health Technology |
Pharma-Lizenz-Club Deutschland | |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Develops novel immunotherapy treatments for cancer and autoimmune disease | Health Technology |
- Stock Market
- Insiders
- Marc Voigt
